"recombinant flt3 ligand Colorectal Cancer" Channels RSS

05:39 EDT 24th October 2017 | BioPortfolio

BioPortfolio's Channels offers visitors a single point of access to life science and healthcare subjects, technologies, products and services. For example ImmTAC developed by Immunocore, PolyXen developed by Xenetic Biosciences. Each dedicated Channel web page provides highly specific information sourced from BioPortfolio's unique collection of databases - news stories, corporate directory, clinical trials, medical and scientific information.

Organizations can request specific channel pages to be created to promote their products, technologies, research tools and services. BioPortfolio makes a nominal charge of between $40 to $50 per web page published. Each bespoke Channel page is managed by the registered member who can edit and amend over the 12 month subscription period. To start publishing content on BioPortfolio's Channels open

Interested? Contact

Showing "recombinant flt3 ligand Colorectal Cancer" Channels 1–25 of 110


Jobs in Colorectal

Proliferation inducing ligand APRIL

Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.

Notch Pathway Inhibitors DLL4

The Notch signaling pathway has been found to play central roles in humans in stem cell maintenance, cell fate decisions, and in cancer as well. Notch family members are being revealed as oncogenes in an ever-increasing number of cancers. Notch signaling...

Recombinant cytokines

Nuclear Factor kB Ligand RANKL Mab rDNA

Hereditary Nonpolyposis Colorectal Carcinoma

Epithelial cell adhesion molecule EpCAM CD326

Epithelial cell adhesion molecule (EpCAM; CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer. Overexpression of EpCAM has ...

Zaltrap (aflibercept)

ZALTRAP®, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.

Human Epidermal Growth Factor receptor EGF R

The human epidermal growth factor receptor (HER) family members include EGFR (erbB1), HER2/neu (erbB2), HER3 (erbB3), and HER4 (erbB4) that are structurally related, and all except HER3 contain intracellular tyrosine kinase (tk) domain. All of the HER me...


Fluorescent in situ hybridization (FISH) is a sensitive and accurate technique that allows the detection of chromosome aberrations. In this method, a single-stranded fluorescent-labeled nucleic acid sequence (probe) complementary to a target genomic sequ...

Tumor markers

Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. These substances can be found in the blood, in the urine, in the tumor tissue, or in other tissues. Diff...

Probably Relevant

Neoadjuvant therapy

Neoadjuvant therapy is the administration of therapeutic agents before the main treatment. One example is neoadjuvant hormone therapy prior to radical radiotherapy for adenocarcinoma of the prostate. The aim of neoadjuvant therapy is to reduce the size o...

Anorectal Cancer

Cancer Diagnosis

Cancer Screening

Endometrial Cancer

Esophageal Cancer

Genitourinary Cancer

Incurable Cancer

Laryngeal Cancer

Nasopharyngeal Cancer

Penile Cancer

Rectal cancer

Vaginal Cancer

Prostate Cancer in Men

Prostate cancer is the most common cancer in men in the UK; affecting 250,000 men. Risk factors for prostate cancer include age (average age at diagnosis is 70), a family history and a Caribbean or African ethnicity. Treatment options  depend on whe...

Quick Search

Channels Quicklinks